Drug Trial Radar · NCT03888716
A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease
Last checked: Nov 19, 2026Latest source record: Oct 20, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
72
Actual
Start
Mar 18, 2019
Primary completion
Mar 16, 2021
Study completion Mar 16, 2021
Sponsor
- Lead sponsor
- Abliva ABIndustry
- Sponsor type
- Industry
- First posted
- Mar 25, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This will be a double blind, randomised, placebo controlled, single and multiple oral dose study conducted in 3 parts: Part A, Part B and Part C. Part A and Part B include healthy volunteers only and will be completed before Part C including patients with primary mitochondrial disease will be initiated. The starting dose in the first cohort of Part A will be 25 mg. The dose level in the additional cohorts will be decided following review of data of the previous cohorts.
Conditions
- Mitochondrial Diseases
- Mitochondrial Respiratory Chain Deficiencies
- MELAS Syndrome
- Mitochondrial Myopathies
Interventions
KL1333Drug
25 and 100 mg KL1333 encapsulated tablets
Placebo Oral TabletDrug
25 and 100 mg placebo encapsulated tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety: incidence and severity of AEsTime frame: Day 15
- Safety: incidence of laboratory abnormalities, based on haematology, clinical chemistry, and urinalysis test resultsTime frame: Day 15
- Safety: 12 lead ECG parametersTime frame: Day 15
- Safety: Number of participants with clinically significant abnormal vital signs measurementsTime frame: Day 15
- Safety: Number of participants with clinically significant abnormal physical examinationsTime frame: Day 15
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
UCL
London, United Kingdom
Covance Leeds
Leeds, West Yorkshire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.